Index | Stable condition(n = 46) | Clinical remission (n = 74) | Clinical disease progression (n = 65) | |||
---|---|---|---|---|---|---|
Baseline level (95%CI) | One year later (95%CI) | Baseline level (95%CI) | One year later (95%CI) | Baseline level (95%CI) | One year later (95%CI) | |
ALT, U/L | 41.17 ± 65.88 (21.61–60.74) | 25.26 ± 21.11# (18.99–31.53) | 66.55 ± 93.83 (44.82–88.29) | 21.58 ± 13.66## (18.42–24.75) | 39.52 ± 55.32 (25.81–53.23) | 29.61 ± 35.81 (20.24–38.49) |
AST, U/L | 39.09 ± 51.56 (23.77–54.40) | 25.96 ± 18.01## (20.61–31.30) | 60.23 ± 83.49 (40.89–79.57) | 23.96 ± 8.92## (21.89–26.03) | 39.05 ± 48.70 (26.98–51.11) | 29.06 ± 16.79 (24.90–33.22) |
γ-GT, U/L | 33.72 ± 33.50 (23.77–43.67) | 23.07 ± 14.57 (18.74–27.39) | 50.62 ± 51.74 (38.63–62.61) | 26.57 ± 27.40## (20.22–32.92) | 36.69 ± 31.62 (28.86–44.53) | 30.58 ± 28.16 (23.61–37.56) |
Tim3, pg/mL | 800.93 ± 520.55 (646.34–955.51) | 712.20 ± 428.81 (584.86–839.54) | 991.41 ± 792.25 (807.86–1174.96) | 644.67 ± 431.30## (544.74–744.59) | 806.94 ± 519.25 (678.28–935.60) | 629.07 ± 337.39# (545.47–712.67) |
Inflammation Grade | 1.30 ± 0.47 (1.17–1.44) | 1.28 ± 0.46 (1.15–1.42) | 2.15 ± 0.69 (1.99–2.31) | 1.22 ± 0.48## (1.11–1.33) | 1.22 ± 0.60 (1.07–1.36) | 1.63 ± 0.601# (1.48–1.78) |
Fibrosis Stage | 1.24 ± 0.90 (0.97–1.51) | 1.20 ± 0.86 (0.94–1.45) | 1.97 ± 1.01 (1.74–2.21) | 1.05 ± 0.98## (0.83–1.28) | 0.62 ± 0.74 (0.43–0.80) | 1.77 ± 0.825# (1.56–1.97) |